Effect of Polymorphism of the β2-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma
暂无分享,去创建一个
Scott T. Weiss | Edwin K. Silverman | Vernon M. Chinchilli | Homer A. Boushey | Jean G. Ford | Monica Kraft | Stanley J. Szefler | Christine A. Sorkness | Richard J. Martin | E. Silverman | E. Israel | J. Drazen | H. Boushey | C. Sorkness | S. Liggett | Richard J Martin | S. Peters | C. Yandava | D. Cooper | J. Ford | V. Chinchilli | S. Szefler | S. Lazarus | M. Kraft | J. Fahy | S. Kunselman | J. Fish | D. McLean | R. Cherniack | Jeffrey M. Drazen | Stephen B. Liggett | Elliot Israel | Reuben M. Cherniack | David M. Cooper | John V. Fahy | James E. Fish | Susan Kunselman | Stephen C. Lazarus | Robert F. Lemanske, Jr. | Diane E. McLean | Stephen P. Peters | Chandri N. Yandava | S. Weiss
[1] A. Wanner. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes. , 1995, American journal of respiratory and critical care medicine.
[2] S. Liggett,et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.
[3] E. Silverman,et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.
[4] S. Liggett. Polymorphisms of the β2-Adrenergic Receptor and Asthma , 1997 .
[5] E. Vonesh,et al. Efficient inference for random-coefficient growth curve models with unbalanced data. , 1987, Biometrics.
[6] R. Erickson,et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.
[7] E. Israel,et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. , 1996, The New England journal of medicine.
[8] S. Liggett. Polymorphisms of the beta2-adrenergic receptor and asthma. , 1997, American journal of respiratory and critical care medicine.
[9] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[10] M. Munakata,et al. Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma. , 1995, Thorax.
[11] Christl A. Donnelly,et al. Review papers : Longitudinal studies with continuous responses , 1992 .
[12] I. Hall,et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.
[13] S. Green,et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. , 1995, The Journal of clinical investigation.
[14] I. Hall,et al. Association of Glu 27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects , 1995, The Lancet.
[15] Brian Lipworth,et al. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.
[16] C Summers,et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.
[17] R. Dockhorn,et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. , 1994, The Journal of allergy and clinical immunology.
[18] I. Hall,et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. , 1997, The Journal of allergy and clinical immunology.
[19] J. Kemp,et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.
[20] C. Print,et al. Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.
[21] T. Haahtela,et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.
[22] E. R. Mcfadden,et al. Perspectives in β2-agonist therapy: Vox clamantis in deserto vel lux in tenebris?**☆☆☆★★★ , 1995 .
[23] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[24] S. Green,et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.
[25] S. Kesten,et al. Regular vs as-needed inhaled salbutamol in asthma control , 1994, The Lancet.
[26] A. Markham,et al. AMPLIFICATION REFRACTORY MUTATION SYSTEM FOR PRENATAL DIAGNOSIS AND CARRIER ASSESSMENT IN CYSTIC FIBROSIS , 1989, The Lancet.
[27] R. Hancox,et al. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. , 1998, The European respiratory journal.
[28] S. Green,et al. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] H. Nelson. β-Adrenergic Bronchodilators , 1995 .